

# **Pegfilgrastim Biosimilar Market is estimated to be US\$ 135.94 billion by 2030 with a CAGR of 19.8% during the forecast period**

[Pegfilgrastim Biosimilar Market](#) accounted for US\$ 2765 million in 2020 and is estimated to be US\$ 16580.8 million by 2030 and is anticipated to register a CAGR of 19.8%. Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, is PEGylated to create Pegfilgrastim. Amgen Inc. originally introduced pegfilgrastim as Neulasta. Pegfilgrastim biosimilars were later introduced to the market. Pegfilgrastim is a supportive oncology medication used to treat neutropenia caused by chemotherapy and/or radiotherapy in cancer patients. With more than ten pegfilgrastim biosimilars on the market and another five in the works, the pegfilgrastim biosimilar size market is projected to grow in the future. On the whole, the COVID-19 pandemic has had a minor impact on the pegfilgrastim market. COVID-19 has sped up clinical trial processes in general, but it is not expected to have a significant impact on regulatory approval processes in the near future.

The report **"Global Pegfilgrastim Biosimilar Market, By Product Class (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes), By Applications (Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"**

## **Key Highlights:**

- The FDA authorised Fujifilm Kyowa Kirin Biologics' adalimumab biosimilar Hulio in July 2020 for the subcutaneous treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
- The regulatory applications for Fresenius Kabi's planned pegfilgrastim biosimilar (MSB11455) were accepted by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in May 2020.

## **Analyst View:**

Strategic alliances are helping companies in the pegfilgrastim biosimilar sector improve their product innovation. Companies are developing novel products and sharing skills and experience with other companies to maintain their place in an increasingly competitive market. While firms have traditionally partnered with one another as well as academic and research organisations in this industry through partnerships, in- or out-licensing agreements, this tendency has accelerated in recent years. Fulphila, produced jointly by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be authorised by the FDA in July 2018. Biocon Biologic Ltd. and the Clinton Health Access Initiative (CHAI) announced a collaboration deal in February 2021 to expand their lifesaving cancer biosimilars in more than 30 African and Asian countries. The collaboration represents a critical step forward in the delivery of sophisticated cancer medicines.

***Before purchasing this report, request a sample or make an inquiry by clicking the following link:***

[https://www.prophecymarketinsights.com/market\\_insight/Insight/request-sample/4811](https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4811)

#### **Key Market Insights from the report:**

Global Pegfilgrastim Biosimilar Market accounted for US\$ 2765 million in 2020 and is estimated to be US\$ 16580.8 million by 2030 and is anticipated to register a CAGR of 19.8%. The Global Pegfilgrastim Biosimilar Market is segmented based on product class, application, distribution channel and region.

- Based on Product Class, Global Pegfilgrastim Biosimilar Market is segmented into Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes.
- Based on Application, Global Pegfilgrastim Biosimilar Market is segmented into Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications.
- Based on Distribution Channel, Global Pegfilgrastim Biosimilar Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- By Region, the Global Pegfilgrastim Biosimilar Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

#### **Competitive Landscape & their strategies of Global Pegfilgrastim Biosimilar Market:**

The market for pegfilgrastim biosimilars is very concentrated and competitive. This biosimilar was created by a number of small and large pharmaceutical businesses. Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG are some of the major companies in the market (Sandoz). These firms have launched pegfilgrastim biosimilars and are bolstering their global market position with partnerships and collaborations. Pfizer Inc, Green Cross Corp, Accord Healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila are among the market's other participants.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.